Ashley Whitechurch
YOU?
Author Swipe
View article: Recommendations for innovation in vaccination services for adults with haematological malignancies: an Australian cross-sectional survey study
Recommendations for innovation in vaccination services for adults with haematological malignancies: an Australian cross-sectional survey study Open
This study has generated world-first evidence investigating the barriers, enablers, and preferences of people affected by haematological malignancies regarding vaccination to inform more acceptable, accessible, and appropriate models of de…
View article: A single‐institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 years
A single‐institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 years Open
Background Allogeneic stem cell transplantation (alloSCT) is an established potentially curative therapy for patients with high‐risk chronic lymphocytic leukaemia (CLL). Future availability of chimeric antigen receptor T‐cell therapies and…
View article: Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers Open
Integration of clinical pharmacogenomics (PGx) within routine cancer care is limited despite frequent use of medicines impacted by PGx, evidence for the benefits of PGx, and the availability of international PGx clinical guidelines. Our st…
View article: “It's a risk-benefit analysis”: Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia
“It's a risk-benefit analysis”: Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia Open
Barriers and enablers to vaccination identified suggest ways in which vaccination services for this population can be improved. While patients receiving vaccinations at their treating centre reported coordinated care that made access strai…
View article: Elucidating novel immune profiles for predicting infection in high‐risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia
Elucidating novel immune profiles for predicting infection in high‐risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia Open
Objectives Chronic lymphocytic leukaemia (CLL) patients are at increased risk for infection, with the risk even higher for relapsed and refractory patients. Clinical assessment of infection risk is increasingly challenging in the era of im…
View article: Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial
Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial Open
Background Medication nonadherence is a serious problem in cancer, potentially impacts patients’ health outcomes and health care costs. Although technology-based medication adherence (MA) interventions have emerged, evidence supporting the…
View article: Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial (Preprint)
Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial (Preprint) Open
BACKGROUND Medication nonadherence is a serious problem in cancer, potentially impacts patients’ health outcomes and health care costs. Although technology-based medication adherence (MA) interventions have emerged, evidence supporting th…
View article: Safety and adherence to medications and self-care advice in oncology (SAMSON): pilot randomised controlled trial protocol
Safety and adherence to medications and self-care advice in oncology (SAMSON): pilot randomised controlled trial protocol Open
Introduction With the increasing use of oral anti-cancer medicines (OAMs), research demonstrating the magnitude of the medication non-adherence problem and its consequences on treatments’ efficacy and toxicity is drawing more attention. Mo…
View article: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care Open
Venetoclax, a highly selective, oral B-cell lymphoma 2 inhibitor, provides a robust targeted-therapy option for the treatment of chronic lymphocytic leukemia (CLL), including patients with high-risk del(17p)/mutated-TP53 and immunoglobulin…
View article: Co-Design, Development, and Evaluation of a Mobile Solution to Improve Medication Adherence in Cancer: Design Science Research Approach
Co-Design, Development, and Evaluation of a Mobile Solution to Improve Medication Adherence in Cancer: Design Science Research Approach Open
Background Medication nonadherence negatively impacts the health outcomes of people with cancer as well as health care costs. Digital technologies present opportunities to address this health issue. However, there is limited evidence on ho…
View article: Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells Open
Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond poorly to vaccination. Relative deficits in immunity are, however, unclear, especially after 3 vaccine doses. We evaluated immune responses in hematology p…
View article: Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy
Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy Open
Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COV…
View article: Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)
Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD) Open
Background Patients with CLL are vulnerable to COVID-19 infection and complications due to underlying immunosuppression and B-cell depleting/targeted therapy (Chatzikonstantinou, Leukemia 2021). Furthermore, CLL patients have reduced seroc…
View article: Disabled, invisible and dismissed—The lived experience of fatigue in people with myeloproliferative neoplasms
Disabled, invisible and dismissed—The lived experience of fatigue in people with myeloproliferative neoplasms Open
Background Myeloproliferative neoplasms (MPNs) are rare haematological cancers. Several studies report the most common MPN symptom leading to reduced quality of life is fatigue. Yet, how fatigue affects the lives of people with MPN is not …